ACRO Biomedical Co., Ltd. (6748.TWO)
TWD 25.7
(-2.1%)
TWD 25.7
(-2.1%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 51.06 Million | 27.63 Million | 21.82 Million | 18.03 Million | - |
| Cost of Revenue | 11.94 Million | 14.2 Million | 7.28 Million | 9.45 Million | - |
| Gross Profit | 39.11 Million | 13.42 Million | 14.54 Million | 8.57 Million | - |
| Operating Expenses | 39.11 Million | 76.2 Million | 68.09 Million | 64.54 Million | - |
| Selling, General and Administrative Expenses | 55.59 Million | 48.35 Million | 42.05 Million | 32.83 Million | - |
| Research and Development Expenses | 28.64 Million | 27.84 Million | 26.04 Million | 31.7 Million | - |
| Other Expenses | - | 1.19 Million | 2.55 Million | 5.83 Million | - |
| Cost and Expenses | 96.18 Million | 90.4 Million | 75.38 Million | 73.99 Million | - |
| Operating Income | -45.11 Million | -60.78 Million | -50.68 Million | -49.91 Million | - |
| Interest Expense | 262 Thousand | 100 Thousand | 88 Thousand | 103 Thousand | 122 Thousand |
| Income Tax Expense | - | - | - | - | - |
| Earnings before Tax | -41.41 Million | -60.88 Million | -50.77 Million | -50.01 Million | - |
| Net Income | -41.41 Million | -60.88 Million | -50.77 Million | -50.01 Million | - |
| Earnings Per Share Basic | -0.79 | -1.29 | -1.43 | -1.65 | -2.43 |
| Earnings Per Share Diluted | -0.79 | -1.29 | -1.43 | -1.65 | -2.43 |
| Weighted Average Shares Outstanding | 52.69 Million | 47.37 Million | 35.5 Million | 30.31 Million | 25.17 Million |
| Weighted Average Shares Outstanding (Diluted) | 52.42 Million | 47.37 Million | 35.5 Million | 30.31 Million | 30.31 Million |
| Gross Margin | 0.77 | 0.49 | 0.67 | 0.48 | - |
| EBIT Margin | -0.59 | -1.87 | -1.89 | -2.07 | - |
| Profit Margin | -0.81 | -2.20 | -2.33 | -2.77 | - |
| EBITDA | -30.18 Million | -51.57 Million | -41.18 Million | -37.37 Million | -45.16 Million |
| Earnings Before Tax Margin | -0.88 | -2.20 | -2.32 | -2.77 | - |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 21.04 Million | 51.06 Million | 35.26 Million | 15.8 Million | 27.63 Million | 15.41 Million |
| Cost of Revenue | 13.08 Million | 11.94 Million | 10.25 Million | 9.81 Million | 14.2 Million | 12.12 Million |
| Gross Profit | 7.96 Million | 39.11 Million | 25 Million | 5.99 Million | 13.42 Million | 3.28 Million |
| Operating Expenses | 37.41 Million | 84.23 Million | 40.99 Million | 38.67 Million | 76.2 Million | 39.33 Million |
| Selling, General and Administrative Expenses | 25.08 Million | - | 26.45 Million | 24.56 Million | - | 23.32 Million |
| Research and Development Expenses | 12.32 Million | - | 14.53 Million | 14.1 Million | - | 16 Million |
| Other Expenses | - | 5.18 Million | - | - | 1.19 Million | - |
| Cost and Expenses | 50.49 Million | 96.18 Million | 51.25 Million | 48.48 Million | 90.4 Million | 51.45 Million |
| Operating Income | -29.45 Million | -37.6 Million | -15.98 Million | -32.68 Million | -60.78 Million | -36.04 Million |
| Interest Expense | 151 Thousand | 262 Thousand | 158 Thousand | 104 Thousand | 100 Thousand | 48 Thousand |
| Income Tax Expense | 17 Thousand | - | 6.24 Million | 1.27 Million | - | 1.69 Million |
| Earnings before Tax | -26.33 Million | -41.41 Million | -9.9 Million | -31.51 Million | -60.88 Million | -34.39 Million |
| Net Income | -26.35 Million | -41.41 Million | -9.9 Million | -31.51 Million | -60.88 Million | -34.39 Million |
| Earnings Per Share Basic | -0.43 | - | -0.17 | -0.61 | - | -0.67 |
| Earnings Per Share Diluted | -0.43 | - | -0.17 | -0.61 | - | -0.67 |
| Weighted Average Shares Outstanding | 61.21 Million | 47.37 Million | 58.02 Million | 51.48 Million | 47.37 Million | 51.48 Million |
| Weighted Average Shares Outstanding (Diluted) | 61.21 Million | 52.42 Million | 58.02 Million | 51.48 Million | 47.37 Million | 51.48 Million |
| Gross Margin | 0.38 | 0.77 | 0.71 | 0.38 | 0.49 | 0.21 |
| EBIT Margin | -0.95 | - | -0.11 | -1.66 | - | -1.93 |
| Profit Margin | -1.25 | -0.81 | -0.28 | -1.99 | -2.20 | -2.23 |
| EBITDA | -20.08 Million | - | -3.93 Million | -26.24 Million | - | -29.66 Million |
| Earnings Before Tax Margin | -1.40 | -0.74 | -0.45 | -2.07 | -2.20 | -2.34 |
NVP8
SPANDANA
ROG
3571
PBL
003200